|
Aug 8
|
Press Release: Sarclisa induction treatment demonstrated significantly improved progression-free survival in patients with newly diagnosed multiple myeloma eligible for transplant
|
|
Aug 6
|
Vir Bio trims staff and pipeline to focus on Sanofi-licensed programmes
|
|
Jul 26
|
Fluzone® High-Dose Quadrivalent vaccine remains preferentially recommended to protect adults 65 years of age and older against influenza
|
|
Jul 26
|
Pharma Stock Roundup: AZN, SNY, ABBV Q2 Earnings, PFE & MRK's Positive Pipeline News
|
|
Jul 25
|
AstraZeneca Says It Has A 'Powerful' — And Differentiated — Approach To Obesity Treatment
|
|
Jul 25
|
Sanofi (SNY) Q2 2024 Earnings Call Transcript
|
|
Jul 25
|
Ontario Ministry of Health Announces a Universal Public Program with Beyfortus® this RSV Season
|
|
Jul 25
|
Press Release: Online availability of Sanofi’s half-year financial report for 2024
|
|
Jul 25
|
Sanofi (SNY) Q2 Earnings Beat, Sales Miss, 2024 View Raised
|
|
Jul 25
|
Sanofi Raises 2024 Profit Outlook On Strong Q2 Earnings, Blockbuster Drug Dupixent Sees Strong Demand
|
|
Jul 25
|
Sanofi’s immunology bet starts to pay off
|
|
Jul 25
|
Sanofi: Q2 Earnings Snapshot
|
|
Jul 25
|
Sanofi lifts 2024 profit forecast on strength in Dupixent, new products
|
|
Jul 25
|
Press Release: Sanofi Q2 - strong performance with 10% sales growth; 2024 guidance upgraded
|
|
Jul 24
|
The Zacks Analyst Blog Highlights Boston Scientific, Thermo Fisher Scientific, Align Technology and Edwards Lifesciences
|
|
Jul 23
|
Merck Competes With Sanofi/AstraZeneca As Its RSV Treatment Drug Meets Primary Goal In Late-Stage Study In Infants
|
|
Jul 23
|
Will These 5 Medical Stocks Surpass Q2 Earnings Forecasts?
|
|
Jul 23
|
Novavax's (NVAX) Shares Surge 211% YTD: Time to Buy the Stock?
|
|
Jul 23
|
Analysis-Drug giants eye China for deals despite growing Sino-US tensions
|
|
Jun 27
|
Formation Bio secures $372m funds for AI-driven drug platform
|